Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 68

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 8
Chunk 68
---
$59 $2,405 $2,307 $98 Other revenues6 3 3 10 8 2 1,278 1,216 62 2,415 2,315 100 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)523 482 41 1,004 905 99 Cost of other revenues2 1 1 3 2 1 Selling, general and administrative (Note 4)579 535 44 1,142 1,039 103 Research and development96 84 12 182 166 16 Amortization of intangible assets67 74 (7)134 148 (14)Other expense, net22 14 8 44 23 21 1,289 1,190 99 2,509 2,283 226 Operating (loss) income(11)26 (37)(94)32 (126)Interest income3 3 — 6 6 — Interest expense(128)(102)(26)(222)(201)(21)Loss on extinguishment of debt(9)— (9)(9)— (9)Foreign exchange and other(2)(3)1 (8)(3)(5)Loss before provision for income taxes(147)(76)(71)(327)(166)(161)Benefit from (provision for income taxes)89 (72)161 58 (145)203 Net loss(58)(148)90 (269)(311)42 Net income attributable to noncontrolling interest(4)(3)(1)(5)(7)2 Net loss attributable to Bausch + Lomb Corporation$(62)$(151)$89 $(274)$(318)$44 

38

Three Months Ended June 30, 2025 Compared to the Three Months Ended June 30, 2024Revenues Our revenues are primarily generated from product sales in the therapeutic areas of eye health that consist of: (i) branded prescription eye-medications and pharmaceuticals, (ii) generic and branded generic prescription eye medications and pharmaceuticals, (iii) OTC vitamin and supplement products and (iv) medical devices (contact lenses, IOLs and ophthalmic surgical equipment). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue